Harlequin Ichthyosis Medication
- Author: Julie Prendiville, MBBCh; Chief Editor: Dirk M Elston, MD more...
Enhanced survival and decreased morbidity is reported with the use of systemic retinoids; however, infants have survived without systemic retinoid therapy. Retinoids bind to specific retinoic acid receptors and regulate gene transcription. They influence keratinocyte differentiation, normalize abnormal keratinocyte proliferation, and mediate desquamation of hyperkeratotic scale. Rajpopat et al recommend frequent application of emollients to ease this shedding of thick plates when retinoids are given.
Etretinate was first used for the treatment of this disorder in 1985. An effective dose of 1 mg/kg/d was established. Etretinate is no longer available and has been replaced by other retinoids with improved safety profiles.
Acitretin, a carboxylic acid derivative of etretinate, is the retinoid most commonly prescribed in neonates with harlequin ichthyosis.[9, 25] Initial doses of 0.5 mg/kg/d are recommended. Improvement in hyperkeratosis, ectropion, and eclabium is reported. The duration of therapy is variable, and continuous, long-term, daily therapy may be required. The daily dose can be titrated to the degree of ichthyosis.
Rajpopat et al reported that of 24 babies given oral retinoids, 20 received acitretin, 2 received etretinate, and 2 received isotretinoin. Twenty of the 24 treated patients survived (83%).
A topical retinoid (tazarotene) has been used to treat local and mechanical circulatory problems caused by hyperkeratosis.[21, 22]
Isotretinoin has also been used in harlequin ichthyosis. The reported dose is 0.5 mg/kg/d. Treatment is usually initiated within the first few days of life and given orally. Case reports have documented improvement in pliability of the skin, limb movements, sucking, and eyelid closing within a week of starting therapy. Treatment has been continued for several years in some patients.
Liver function and serum lipid levels should be monitored during retinoid therapy. Clinical monitoring for skeletal adverse effects should be done periodically. Before retinoid therapy is considered, discuss the expected outcome and the potential adverse effects with the parents.
These agents decrease the cohesiveness of abnormal hyperproliferative keratinocytes. They modulate keratinocyte differentiation.
Synthetic 13-cis isomer of naturally occurring tretinoin (trans -retinoic acid). Both agents structurally related to vitamin A.
A US Food and Drug Administration–mandated registry is now in place for all individuals prescribing, dispensing, or taking isotretinoin. For more information on this registry, see iPLEDGE. This registry aims to further decrease the risk of pregnancy and other unwanted and potentially dangerous adverse effects during a course of isotretinoin therapy.
Metabolite of etretinate and related to retinoic acid and retinol (vitamin A). Mechanism of action unknown but thought to exert therapeutic effect by modulating keratinocyte differentiation, keratinocyte hyperproliferation, and tissue infiltration by inflammatory cells.
Oji V, Tadini G, Akiyama M, Blanchet Bardon C, Bodemer C, Bourrat E. Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009. J Am Acad Dermatol. 2010 Oct. 63(4):607-41. [Medline].
Lawlor F. Progress of a harlequin fetus to nonbullous ichthyosiform erythroderma. Pediatrics. 1988 Dec. 82(6):870-3. [Medline].
Ahmed H, O'Toole EA. Recent advances in the genetics and management of harlequin ichthyosis. Pediatr Dermatol. 2014 Sep-Oct. 31 (5):539-46. [Medline].
Rajpopat S, Moss C, Mellerio J, et al. Harlequin ichthyosis: a review of clinical and molecular findings in 45 cases. Arch Dermatol. 2011 Jun. 147(6):681-6. [Medline].
Shibata A, Akiyama M. Epidemiology, medical genetics, diagnosis and treatment of harlequin ichthyosis in Japan. Pediatr Int. 2015 Aug. 57 (4):516-22. [Medline].
Lefevre C, Audebert S, Jobard F, et al. Mutations in the transporter ABCA12 are associated with lamellar ichthyosis type 2. Hum Mol Genet. 2003 Sep 15. 12(18):2369-78. [Medline].
Akiyama M. ABCA12 mutations and autosomal recessive congenital ichthyosis: a review of genotype/phenotype correlations and of pathogenetic concepts. Hum Mutat. 2010 Oct. 31(10):1090-6. [Medline].
Akiyama M. The roles of ABCA12 in epidermal lipid barrier formation and keratinocyte differentiation. Biochim Biophys Acta. 2014 Mar. 1841(3):435-440. [Medline].
Elias PM, Williams ML, Holleran WM, Jiang YJ, Schmuth M. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res. 2008 Apr. 49(4):697-714. [Medline]. [Full Text].
Scott CA, Rajpopat S, Di WL. Harlequin ichthyosis: ABCA12 mutations underlie defective lipid transport, reduced protease regulation and skin-barrier dysfunction. Cell Tissue Res. 2013 Feb. 351(2):281-8. [Medline].
Akiyama M, Sugiyama-Nakagiri Y, Sakai K, McMillan JR, Goto M, Arita K, et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest. 2005 Jul. 115(7):1777-84. [Medline]. [Full Text].
Stewart H, Smith PT, Gaunt L, Moore L, Tarpey P, Andrew S, et al. De novo deletion of chromosome 18q in a baby with harlequin ichthyosis. Am J Med Genet. 2001 Sep 1. 102(4):342-5. [Medline].
Thomas AC, Tattersall D, Norgett EE, O'Toole EA, Kelsell DP. Premature terminal differentiation and a reduction in specific proteases associated with loss of ABCA12 in Harlequin ichthyosis. Am J Pathol. 2009 Mar. 174(3):970-8. [Medline].
Berg C, Geipel A, Kohl M, Krokowski M, Baschat AA, Germer U, et al. Prenatal sonographic features of Harlequin ichthyosis. Arch Gynecol Obstet. 2003 Apr. 268(1):48-51. [Medline].
Bongain A, Benoit B, Ejnes L, Lambert JC, Gillet JY. Harlequin fetus: three-dimensional sonographic findings and new diagnostic approach. Ultrasound Obstet Gynecol. 2002 Jul. 20(1):82-5. [Medline].
Watson WJ, Mabee LM Jr. Prenatal diagnosis of severe congenital ichthyosis (harlequin fetus) by ultrasonography. J Ultrasound Med. 1995 Mar. 14(3):241-3. [Medline].
Chan YC, Tay YK, Tan LK, Happle R, Giam YC. Harlequin ichthyosis in association with hypothyroidism and juvenile rheumatoid arthritis. Pediatr Dermatol. 2003 Sep-Oct. 20(5):421-6. [Medline].
Milstone LM, Choate KA. Improving outcomes for harlequin ichthyosis. J Am Acad Dermatol. 2013 Nov. 69(5):808-9. [Medline].
Chua CN, Ainsworth J. Ocular management of harlequin syndrome. Arch Ophthalmol. 2001 Mar. 119(3):454-5. [Medline].
Koochek A, Choate KA, Milstone LM. Harlequin Ichthyosis: Neonatal Management and Identification of a New ABCA12 Mutation. Pediatr Dermatol. 2014 Mar. 31(2):e63-4. [Medline].
Liu RH, Becker B, Gunkel J, Teng J. Rapid improvement in digital ischemia and acral contracture in a collodion baby treated with topical tazarotene. J Drugs Dermatol. 2010 Jun. 9(6):713-6. [Medline].
Ripmeester P, Dunn S. Against all odds: breastfeeding a baby with harlequin ichthyosis. J Obstet Gynecol Neonatal Nurs. 2002 Sep-Oct. 31(5):521-5. [Medline].
Tontchev G, Silverberg NB, Shlasko E, Henry C, Roberts JL, Roth MZ. Techniques for toddlers: linear band incision for harlequin ichthyosis with associated compartment syndrome. Pediatr Dermatol. 2014 Sep-Oct. 31 (5):625-9. [Medline].
Harvey HB, Shaw MG, Morrell DS. Perinatal management of harlequin ichthyosis: a case report and literature review. J Perinatol. 2010 Jan. 30(1):66-72. [Medline].